Login / Signup

Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.

Victoria P WerthPascal JolyDaniel MimouniEmanual MaverakisFrédéric CauxPatricia LehaneLiudmila GearhartAudrey KaprePooneh PordeliDiana M Chennull null
Published in: The New England journal of medicine (2021)
Rituximab was superior to mycophenolate mofetil in producing sustained complete remission at 52 weeks in patients with pemphigus vulgaris. Rituximab resulted in a greater reduction in glucocorticoid use than mycophenolate mofetil, but more patients in the rituximab group had serious adverse events. Further trials are needed to determine the comparative efficacy and safety of rituximab and mycophenolate mofetil beyond 52 weeks of treatment. (Funded by F. Hoffmann-La Roche; PEMPHIX ClinicalTrials.gov number, NCT02383589.).
Keyphrases